Luke Peterson
About
Luke Peterson is a scholar working on Immunology, Rheumatology and Pathology and Forensic Medicine.
According to data from OpenAlex, Luke Peterson has authored 59 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Immunology, 25 papers in Rheumatology and 15 papers in Pathology and Forensic Medicine. Recurrent topics in Luke Peterson's work include Psoriasis: Treatment and Pathogenesis (49 papers), Spondyloarthritis Studies and Treatments (19 papers) and Rheumatoid Arthritis Research and Therapies (15 papers). Luke Peterson is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (49 papers), Spondyloarthritis Studies and Treatments (19 papers) and Rheumatoid Arthritis Research and Therapies (15 papers). Luke Peterson collaborates with scholars based in United States, Germany and Belgium. Luke Peterson's co-authors include Andrew Blauvelt, Christopher L. Cioffi, Kristian Reich, Alice B. Gottlieb, Richard B. Warren, Nancy Cross, Mark Lebwohl, Richard G. Langley, Kim Papp and Dirk De Cuyper and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Annals of the Rheumatic Diseases.
In The Last Decade
Luke Peterson
54 papers receiving 1.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Luke Peterson United States | 15 | 970 | 480 | 477 | 294 | 175 | 59 | 1.3k | ||
| Manmath Patekar Switzerland | 10 | 921 0.9× | 513 1.1× | 358 0.8× | 396 1.3× | 113 0.6× | 20 | 1.1k | ||
| Isabelle Hampele United States | 6 | 1.3k 1.4× | 344 0.7× | 751 1.6× | 217 0.7× | 261 1.5× | 8 | 1.6k | ||
| Talia M. Muram United States | 11 | 775 0.8× | 206 0.4× | 426 0.9× | 116 0.4× | 133 0.8× | 18 | 972 | ||
| R. You Switzerland | 11 | 1.2k 1.2× | 235 0.5× | 812 1.7× | 174 0.6× | 274 1.6× | 17 | 1.3k | ||
| Ming-Chun Hsu United States | 9 | 1.5k 1.6× | 323 0.7× | 824 1.7× | 232 0.8× | 281 1.6× | 14 | 1.7k | ||
| Kavitha Goyal United States | 12 | 828 0.9× | 204 0.4× | 389 0.8× | 118 0.4× | 130 0.7× | 22 | 1.0k | ||
| H. Bachelez France | 16 | 1.2k 1.3× | 209 0.4× | 822 1.7× | 103 0.4× | 270 1.5× | 41 | 1.4k | ||
| Martina Burlando Italy | 16 | 460 0.5× | 252 0.5× | 357 0.7× | 77 0.3× | 227 1.3× | 96 | 859 | ||
| J.M.P.A. van den Reek Netherlands | 20 | 785 0.8× | 217 0.5× | 470 1.0× | 75 0.3× | 98 0.6× | 41 | 1.1k | ||
| Nikolai Loft Denmark | 18 | 559 0.6× | 228 0.5× | 516 1.1× | 68 0.2× | 76 0.4× | 51 | 1.0k |
Countries citing papers authored by Luke Peterson
Since
Specialization
Citations
This map shows the geographic impact of Luke Peterson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luke Peterson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luke Peterson more than expected).
Fields of papers citing papers by Luke Peterson
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Luke Peterson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luke Peterson. The network helps show where Luke Peterson may publish in the future.
Co-authorship network of co-authors of Luke Peterson
This figure shows the co-authorship network connecting the top 25 collaborators of Luke Peterson. A scholar is included among the top collaborators of Luke Peterson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luke Peterson. Luke Peterson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Blauvelt, Andrew, April W. Armstrong, Joseph F. Merola, et al.. (2024). Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials. Journal of the American Academy of Dermatology. 91(1). 72–81.
2.
Gordon, Kenneth B., Diamant Thaçi, Melinda Gooderham, et al.. (2024). 52671 Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials. Journal of the American Academy of Dermatology. 91(3). AB145–AB145.
3.
Lebwohl, Mark, Joseph F. Merola, Bruce Strober, et al.. (2024). Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials. Journal of the American Academy of Dermatology. 91(2). 281–289.
4.
Gordon, Kenneth B., Richard G. Langley, Richard B. Warren, et al.. (2023). Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials. British Journal of Dermatology. 190(4). 477–485.
5.
Poddubnyy, Denis, Lianne S. Gensler, Philip J. Mease, et al.. (2023). AB0938 SAFETY PROFILE OF BIMEKIZUMAB AT WEEK 16 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS: RESULTS FROM FOUR PLACEBO-CONTROLLED PHASE 3 STUDIES. Annals of the Rheumatic Diseases. 82. 1686–1687.
6.
Garg, Amit, Robert Rolleri, Luke Peterson, et al.. (2023). Validation of the Hidradenitis Suppurativa Investigator Global Assessment. JAMA Dermatology. 159(6). 606–606.
7.
Blauvelt, Andrew, April W. Armstrong, Joseph F. Merola, et al.. (2023). Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Analysis of Mental Health and Associated Disorders. SKIN The Journal of Cutaneous Medicine. 7(6). s300–s300.
8.
Warren, Richard B., et al.. (2021). Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 Trials. Dermatology and Therapy. 11(5). 1551–1569.
9.
Blauvelt, Andrew, Joseph F. Merola, Kim Papp, et al.. (2020). 14020 Durability of responses with bimekizumab, a selective dual inhibitor of interleukin-17A and -17F, in moderate to severe chronic plaque psoriasis in a 60-week randomized, double-blinded, phase 2b study (BE ABLE 2). Journal of the American Academy of Dermatology. 83(6). AB16–AB16.
10.
Heijde, Désirée van der, Atul Deodhar, Oliver FitzGerald, et al.. (2018). 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. RMD Open. 4(1). e000582–e000582.
11.
Lebwohl, Mark, Andrew Blauvelt, C. Paul, et al.. (2018). Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). Journal of the American Academy of Dermatology. 79(2). 266–276.e5.
12.
Walsh, Jessica A., T. Arledge, T. Nurminen, Luke Peterson, & J. Stark. (2018). PGA×BSA: A Measure of Psoriasis Severity Tested in Patients with Active Psoriatic Arthritis and Treated with Certolizumab Pegol. The Journal of Rheumatology. 45(7). 922–928.
13.
Papp, Kim, Joseph F. Merola, Alice B. Gottlieb, et al.. (2018). Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. Journal of the American Academy of Dermatology. 79(2). 277–286.e10.
14.
Mease, Philip J., Roy Fleischmann, J. Wollenhaupt, et al.. (2016). CERTOLIZUMAB PEGOL FOR THE TREATMENT OF PSORIATIC ARTHRITIS: 4-YEAR OUTCOMES FROM THE RAPID-PSA TRIAL. Clinical and Experimental Rheumatology. 34(4). 779–780.
15.
Gladman, Dafna D., et al.. (2016). Certolizumab Pegol is Associated with Long-Term Improvements in Patient-Reported Outcomes in Psoriatic Arthritis: 4-Year Outcomes from the Rapid-Psa Study. Value in Health. 19(7). A594–A594.
16.
Burmester, Gerd‐Rüdiger, Bernard Combe, Jeffrey R. Curtis, et al.. (2016). Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. The Lancet. 388(10061). 2763–2774.
17.
Mease, Philip, et al.. (2014). Long-Term Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Psoriatic Arthritis with and without Prior Tumor Necrosis Factor Inhibitor Exposure. Data Archiving and Networked Services (DANS).
18.
Gladman, Dafna D., et al.. (2014). Long-Term Maintenance of Improvements in Multiple Facets of Psoriatic Arthritis With Certolizumab Pegol: 96-Week Patient-Reported Outcome Results Of The Rapid-Psa Study. Value in Health. 17(7). A386–A386.
19.
Wollenhaupt, J., D. Gladman, C. Stach, et al.. (2013). Effect Of Certolizumab Pegol Over 48 Weeks On Signs and Symptoms In Patients With Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Exposure. The Journal of Rheumatology. 41(7). 1448–1449.
20.
Gladman, Dafna D., et al.. (2013). Long-Term Maintenance of Improvements in Multiple Facets of Psoriatic Arthritis with Certolizumab Pegol: 48-Week Patient-Reported Outcome Results of the Rapid-PsA Study. Value in Health. 16(7). A569–A569.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Manmath Patekar Breakdown of academic impact, for papers by Isabelle Hampele Breakdown of academic impact, for papers by Talia M. Muram Breakdown of academic impact, for papers by R. You Breakdown of academic impact, for papers by Ming-Chun Hsu Breakdown of academic impact, for papers by Kavitha Goyal Breakdown of academic impact, for papers by H. Bachelez Breakdown of academic impact, for papers by Martina Burlando Breakdown of academic impact, for papers by J.M.P.A. van den Reek Breakdown of academic impact, for papers by Nikolai Loft